ERBB2 and breast carcinoma: Treating HER2+ BC with trastuzumab in combination with chemotherapy across the neoadjuvant, adjuvant, and advanced breast cancer (ABC) settings improves patient outcomes, including disease-free survival (DFS) and overall survival (OS).